06.07.2022 • NewsPolyntplasticizer

Polynt Plans Plasticizer Plant in Mexico

Polynt, an Italian manufacturer of chemical intermediates, is planning to build a new esterification plant to produce plasticizers – and mainly trimellitates – at its site in Atlacomulco, Mexico, in order to meet rising demand.

© Polynt
© Polynt

Design and permitting activities will start during the second half of 2022, while construction is scheduled to take place next year. The new plant will use some equipment from Polynt’s trimellitates plant in Changzhou, China, which closed in 2021. Mechanical completion is anticipated by the end of 2023, with start-up scheduled for the first quarter of 2024.

Polynt explained that because of their superior technical performance in electrical and high-temperature applications, high-performance plasticizers are a major component for the electrification of cars and transportation, with trimellitates being the most effective product family for satisfying those particular performance properties.

In separate news, the Bergamo-based firm said it has also decided to expand capacity for coating resins in North America. The expansion will be fully effective by 2023 to meet the growing needs of the region’s paint and coatings industry with alkyd, polyester, copolymer, emulsion and urethane resin technologies. The company did not disclose any other details on the project.

Polynt – formerly Polynt-Reichhold – is owned by UK private equity group Black Diamond Capital Management, which took over as controlling shareholder in July 2021.

Author: Elaine Burridge, Freelance Journalist

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.